高风险APOL1基因型局灶节段性肾小球硬化患者病情快速进展
在CureGN队列650例经活检诊断的FSGS患者中,476例(73%)接受基因检测,87例(18%)为高风险APOL1基因型;高风险组中位eGFR低于低风险组(62 vs 76 ml/min per 1.73 m²,P<0.01)。校正分析显示高风险组eGFR更快进展的比值比为2.75(95%CI 1.67–4.53,P<0.001)。结论认为高风险APOL1基因型是FSGS患者肾功能更快丢失的主要相关因素。
要点
- FSGS患者中高风险APOL1基因型与更快的eGFR下降相关,校正后OR为2.75。
- 高风险组中位eGFR为62 ml/min per 1.73 m²,低于低风险组的76 ml/min per 1.73 m²。
- CureGN队列中476例FSGS患者接受基因检测,87例(18%)为高风险APOL1基因型。
核心结论
- 在FSGS患者中,高风险APOL1基因型是肾功能更快丢失的主要相关因素。
研究设计与样本
- CureGN队列研究,纳入经活检诊断的FSGS患者,无论自我认定的种族。
- 暴露为两个APOL1风险等位基因(高风险)对比零至一个风险等位基因(低风险)。
- 主要结局为eGFR斜率,分为快速进展者(斜率≤-5 ml/min per year)、中间进展者(斜率0至-5之间)和无进展者(斜率≥0)。
主要发现
- 650例参与者中,476例(73%)接受基因检测,其中87例(18%)为高风险。
- 高风险组中位eGFR为62 ml/min per 1.73 m²(四分位距36–81),低风险组为76 ml/min per 1.73 m²(四分位距44–106),P<0.01。
- 校正分析中,高风险组eGFR更快进展的比值比为2.75(95%CI 1.67–4.53,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FSGS is a heterogeneous diagnosis with a guarded prognosis. Polymorphisms in the apolipoprotein L1 ( APOL1 ) gene are associated with developing FSGS and faster progression to kidney failure in affected patients. Better understanding the natural history of patients with FSGS and APOL1 risk alleles is essential to improve patient care and support the design and interpretation of interventional studies. The objective of this study was to evaluate the quantitative association between APOL1 and kidney disease progression and the interaction with other clinical and laboratory factors. METHODS: CureGN cohort study participants with biopsy diagnosis of FSGS, regardless of self-identified race, were included. The exposure of interest was two APOL1 risk alleles (high risk) versus zero to one risk alleles (low risk). The primary outcome was eGFR slope categorized as rapid progressor (eGFR slope ≤-5 ml/min per year), intermediate progressor (slope between 0 and -5), or nonprogressor (slope ≥0). Multivariable ordinal logistic and linear regressions were used for adjusted analyses. Missing data were addressed using multiple imputation. RESULTS: Of 650 participants, 476 (73%) had genetic testing, among whom 87 (18%) were high risk. High-risk participants were more likely to have lower median eGFR (62 [interquartile range, 36-81] versus low-risk participants 76 ml/min per 1.73 m 2 [interquartile range, 44-106]; P <0.01). In adjusted analysis, the odds of more rapid progression of eGFR was 2.75 times higher (95% confidence interval, 1.67 to 4.53; P <0.001) in the high-risk versus low-risk groups. CONCLUSIONS: In patients with FSGS, high-risk APOL1 genotype is the predominant factor associated with more rapid loss of kidney function.
引用
- Kallash M, Wang Y, Smith A, et al. Rapid Progression of Focal Segmental Glomerulosclerosis in Patients with High-Risk APOL1 Genotypes. Clin J Am Soc Nephrol. 2023. PMID: 36763813. doi:10.2215/CJN.0000000000000069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。